Analytical instrument developer Abselion raises £6.6m in Series A funding
Cambridge-based Abselion has secured £6.6 million in Series A financing to commercialise its Amperia protein analyser system, which enables rapid at-line quantification of antibodies, AAVs and other proteins from crude samples. The funding round was led by M Ventures, with participation from new and existing investors.